Novavax (NVAX) shares added ~6% in the premarket on Wednesday after the COVID-19 vaccine maker well exceeded Street forecasts with its Q1 financials, thanks to a licensing deal with Pfizer (PFE) ...

Pfizer has been leaning on recently acquired products to offset a looming patent cliff.

The company posted $389 million in first-quarter revenue, well above analyst expectations, with 80% coming from international ...

Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is ...

Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...

Moderna (MRNA) stock jumps after Q1 2026 earnings beat on strong international COVID vaccine sales, despite wider loss driven ...

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...